|
Originally published In Press as doi:10.1074/jbc.M403628200 on November 1, 2004
J. Biol. Chem., Vol. 280, Issue 2, 1007-1015, January 14, 2005
Characterization of the Alzheimer's Disease-associated CLAC Protein and Identification of an Amyloid -Peptide-binding Site*
Linda Söderberg ,
Hiroyoshi Kakuyama ,
Anna Möller ,
Akira Ito¶,
Bengt Winblad ,
Lars O. Tjernberg , and
Jan Näslund
From the
Karolinska Institutet and Sumitomo Pharmaceuticals Alzheimer Center, Neurotec, Novum, SE-141 57 Huddinge, Sweden and the ¶Sumitomo Pharmaceuticals Research Center, Osaka 554-0022, Japan
Amyloid -peptide (A ) deposition into amyloid plaques is one of the invariant neuropathological features of Alzheimer's disease. Other proteins co-deposit with A in plaques, and one recently identified amyloid-associated protein is the collagen-like Alzheimer amyloid plaque component CLAC. It is not known how CLAC deposition affects A plaque genesis and the progress of the disease. Here, we studied the in vitro properties of CLAC purified from a mammalian expression system. CLAC displays features characteristic of a collagen protein, e.g. it forms a partly protease-resistant triple-helical structure, exhibits an intermediate affinity for heparin, and is glycosylated. Purified CLAC was also used to investigate the interaction between CLAC and A . Using a solid-phase binding assay, we show that CLAC bound with a similar affinity to aggregates formed by A -(140) and A -(142) and that the interaction was impaired by increasing salt concentrations. An 8-residue-long sequence located in non-collagenous domain 2 of CLAC was found to be crucial for the interaction with A . These findings may be useful for future therapeutic interventions aimed at finding compounds that modulate the binding of CLAC to A deposits.
Received for publication, April 1, 2004
, and in revised form, October 25, 2004.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Karolinska Inst., Neurotec, Novum Kaspac Plan 5, SE-141 57 Huddinge, Sweden. Tel.: 46-8-585-836-21; Fax: 46-8-585-836-10; E-mail: linda.soderberg{at}neurotec.ki.se.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Osada, T. Hashimoto, A. Nishimura, Y. Matsuo, T. Wakabayashi, and T. Iwatsubo
CLAC Binds to Amyloid {beta} Peptides through the Positively Charged Amino Acid Cluster within the Collagenous Domain 1 and Inhibits Formation of Amyloid Fibrils
J. Biol. Chem.,
March 4, 2005;
280(9):
8596 - 8605.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|